ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2366

Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Abstract Number: 2367

Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
Abstract Number: 2368

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Abstract Number: 2369

Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis
Abstract Number: 2370

Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus
Abstract Number: 2371

The Role of Intracytoplasmic Toll- Like Receptors (TLR) and MyD88 in B Cell Subsets as Renal Response Predictors in Patients with Lupus Nephritis
Abstract Number: 2372

Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
Abstract Number: 2373

The Construction and Validation of Sub-phenotype-specific Genetic Risk Scores in Systemic Lupus Erythematosus: A Novel Approach Using Large-scale Biobank Data
Abstract Number: 2374

Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia
Abstract Number: 2375

Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?
Abstract Number: 2376

Systemic Lupus Erythematosus Patients Exhibit Dynamic Changes in Disease-Associated Transcripts Following Total Knee or Total Hip Arthroplasty
Abstract Number: 2377

Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY
Abstract Number: 2378

Is Urinary Protein-creatinine Relation Reliable for Diagnosis or Follow up of Lupus Nephritis?
Abstract Number: 2379

Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus
Abstract Number: 2380

Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].